Sangamo BioSciences Reports Second Quarter 2009 Financi... (ensation which totaled $0.8 million in t...)

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

Date:7/29/2009

ensation which totaled $0.8 million in the second quarter of 2009 compared to $0.6 million in the same period in 2008.

Total operating expenses for the second quarter of 2009 were $9.9 million, compared to $10.8 million for the same period in 2008.

Net interest and other income was $0.6 million for the second quarters of both 2009 and 2008.

Six Month Results

For the six months ended June 30, 2009, the consolidated net loss was $11.3 million, or $0.28 per share, compared to a consolidated net loss of $15.4 million, or $0.38 per share, for the six-month period ended June 30, 2008. Revenues were $7.9 million for the first half of 2009, compared to $5.6 million in the same period in 2008. Total operating expenses were $20.1 million for the first half of 2009 and $22.4 million in the first half of 2008. The decrease in operating expenses for 2009 was primarily associated with decreased manufacturing, preclinical and decreased lab supply expenses partially offset by increased clinical trial expenses.

Recent Highlights

Presentation of positive Phase 2 ZFP Therapeutic data at ADA 2009. Sangamo announced the presentation of previously unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA). Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. The data have enabled the definition of a responder population for SB-509 for future clinical trials.
Achievement of key milestone in cell engineering agreement with Genentech. A key research milestone was achieved in Sangamo's Research a
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:6/18/2013)... June 18, 2013 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended March 31, 2013. Fourth Quarter ... fourth quarter of fiscal 2013 increased by 33.3% to ...

(Date:6/18/2013)... PA (PRWEB) June 18, 2013 Demanding ... Ball Lenses engineered of synthetic Sapphire and Glass Ball ... sizes from Swiss Jewel Company , of Philadelphia ... by expanding and collimating the light beams without the ... optical clarity and natural durability (9 mohs) make it ...

(Date:6/18/2013)... RegeneCure announced today the start of a ... (GBR) Dental Membrane as a bone stimulating aid for patients ... patients have a tooth replaced with a dental implant is ... Consequently there is often a need to support the implant ... bone substitute material, in turn, needs to be held in ...

(Date:6/18/2013)... , June 18, 2013 AMRI (NASDAQ: ... Burlington, Mass. , site has ... Enforcement Administration (DEA) registration to handle Schedule 2 ... DEA,s acknowledgement of Burlington,s ... and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...

[0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors [0] RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants [0] AMRI Burlington Receives DEA Approval to Handle Controlled Substances

... 31 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... and Drug Administration (FDA) seeking approval to,market pegloticase in ... review. Savient,s filing includes data from both the six-month,placebo ... from the Open,Label Extension (OLE) study. The data set ...

... 31 /Xinhua-PRNewswire/ -- Sundia MediTech,Company, a Shanghai-based drug ... this year,s Deloitte Technology,Fast 50 China award, and ... 50 China Program was announced today in Shenzhen, ... 50 Program started in 1995 in San Jose. ...

... than a dozen employers in health care, employment continued to increase in ... like no one was searching for those new jobs. , ... Seattle, ... care field, with an average of 30,000 jobs created each month. Even ...

Cached Biology Technology:Savient Submits Biologics License Application (BLA) for pegloticase 2 Savient Submits Biologics License Application (BLA) for pegloticase 3 Savient Submits Biologics License Application (BLA) for pegloticase 4 Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China 2 The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2 The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3

Savient Submits Biologics License Application (BLA) for pegloticase Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health

(Date:6/18/2013)... It is estimated that between 5% and 10% of ... is to say that these tumours are attributable to ... BRCA1 or BRCA2. In patients with these mutations, PARP ... encouraging results that make them a new option for ... the latest studies indicate that a fraction of these ...

(Date:6/18/2013)... LA, London (18 June 2013). A team of internationally ... by Dr Sarah Ellis from the University of Lincoln, ... Clinic, Wisconsin, U.S.A. were invited by the International Society ... Feline Practitioners (AAFP) to compile guidelines for veterinarians, owners ... the environmental needs of the domestic cat. The new ...

(Date:6/17/2013)... MA Women in the U.S. exposed to high levels ... likely to have a child with autism as women who ... study from Harvard School of Public Health (HSPH). It is ... and air pollution across the U.S. , "Our findings raise ... the women in our study lived in areas where risk ...

Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2 Feline behavior experts release guidelines to improve the welfare of cats 2 Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2

[0] An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer [0] Feline behavior experts release guidelines to improve the welfare of cats [0] Exposure to high pollution levels during pregnancy may increase risk of having child with autism

... April 14, 2011 -- The number of couples struggling with ... assisted reproductive technologies, like in vitro fertilization (IVF), to get ... increase the risk of multiple pregnancies (i.e., twins or triplets), ... Twins and triplets are likely to be born prematurely, ...

... 2011 Ceelox, Inc. (OTCBB: CELO) announced today that ... to cloud applications using biometrics. Ceelox ID Online® utilizes ... an Internet server-based biometric software application. This enables users ... credentials, i.e. user name and password, compromised or stolen ...

... The following highlights summarize research papers that have been ... 1. Little Ice Age resulted from more than just ... measure of the amount of light the Sun puts out, ... especially when TSI is notably higher or lower than its ...

Cached Biology News:New study finds stronger regulations of in vitro fertilization may save lives 2 Ceelox Provides Biometric Identity Access to Cloud Applications 2 Ceelox Provides Biometric Identity Access to Cloud Applications 3 AGU journal highlights -- April 13, 2011 2 AGU journal highlights -- April 13, 2011 3 AGU journal highlights -- April 13, 2011 4 AGU journal highlights -- April 13, 2011 5 AGU journal highlights -- April 13, 2011 6 AGU journal highlights -- April 13, 2011 7

New study finds stronger regulations of in vitro fertilization may save lives Ceelox Provides Biometric Identity Access to Cloud Applications AGU journal highlights -- April 13, 2011

...

BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....

... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...

BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...

Biology Products:

Eppendorf Thermomixer R from Eppendorf North America BD BioCoat Collagen IV 35 mm Culture Dishes from BD Biosciences - Discovery Labware Lambda GT11 Forward DNA Sequencing Primer from EPICENTRE Biotechnologies BD BioCoat Matrigel Matrix 35 mm Culture Dishes from BD Biosciences - Discovery Labware